TERT promoter mutation
A mutation that keeps the cell's immortality enzyme switched on. In thyroid cancer, having it alongside BRAF marks the tumours most likely to spread and resist iodine.
C228T and C250T mutations occur in ~10% of papillary and most anaplastic thyroid cancers; co-occurrence with BRAF V600E is synergistic for recurrence, distant metastasis, and mortality. Included in ThyroSeq and used for risk stratification; also a marker in glioma, melanoma, and bladder cancer.
Pages like this
not linked directly; found by shared links- TermBethesda category (thyroid cytology)
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.
- CompanyVeracyte (Decipher)
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.
- IdeaUltrasound restraint and surveillance to reverse thyroid cancer overdiagnosis
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.
- TermBRAF V600E mutation
Shares BRAF, Thyroid cancer, Melanoma.
- TrialCOMBI-AD
- TrialDECISION
Shares BRAF, Thyroid cancer.
- PairingBRAF/MEK inhibition → surgery in anaplastic thyroid cancer
Shares BRAF, Thyroid cancer.
- CollectionMelanoma Research Alliance (MRA)